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BACKGROUND
Observational studies support an association between a low blood 25-hydroxyvitamin 
D level and the risk of type 2 diabetes. However, whether vitamin D supplementation 
lowers the risk of diabetes is unknown.
METHODS
We randomly assigned adults who met at least two of three glycemic criteria for pre-
diabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose 
level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter; and glycated 
hemoglobin level, 5.7 to 6.4%) and no diagnostic criteria for diabetes to receive 4000 IU 
per day of vitamin D3 or placebo, regardless of the baseline serum 25-hydroxyvitamin 
D level. The primary outcome in this time-to-event analysis was new-onset diabetes, 
and the trial design was event-driven, with a target number of diabetes events of 508.
RESULTS
A total of 2423 participants underwent randomization (1211 to the vitamin D group and 
1212 to the placebo group). By month 24, the mean serum 25-hydroxyvitamin D level in 
the vitamin D group was 54.3 ng per milliliter (from 27.7 ng per milliliter at baseline), 
as compared with 28.8 ng per milliliter in the placebo group (from 28.2 ng per milliliter 
at baseline). After a median follow-up of 2.5 years, the primary outcome of diabetes oc-
curred in 293 participants in the vitamin D group and 323 in the placebo group (9.39 
and 10.66 events per 100 person-years, respectively). The hazard ratio for vitamin D as 
compared with placebo was 0.88 (95% confidence interval, 0.75 to 1.04; P = 0.12). The 
incidence of adverse events did not differ significantly between the two groups.
CONCLUSIONS
Among persons at high risk for type 2 diabetes not selected for vitamin D insuffi-
ciency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a 
significantly lower risk of diabetes than placebo. (Funded by the National Institute of 
Diabetes and Digestive and Kidney Diseases and others; D2d ClinicalTrials.gov number, 
NCT01942694.)
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Vitamin D and Prevention of Diabetes
More than 84 million adults in the United States have an increased risk of type 2 diabetes, based on a fasting 
glucose or glycated hemoglobin level above the 
normal range but below the threshold for diabe-
tes.1 Persons at high risk for type 2 diabetes who 
are overweight or obese and who have elevated 
fasting glucose levels and glucose intolerance 
(according to a 75-g oral glucose-tolerance test) 
can slow progression to diabetes with lifestyle 
changes.2 However, achieving and maintaining 
sufficient lifestyle change is challenging, and the 
residual risk of diabetes remains elevated, even 
after successful weight loss.
Over the past decade, a low blood 25-hydroxy-
vitamin D level has emerged as a possible risk 
factor for type 2 diabetes, and vitamin D supple-
mentation has been proposed as a potential in-
tervention to lower diabetes risk.3,4 The hypothe-
sis that vitamin D status may influence the risk 
of type 2 diabetes is biologically plausible, be-
cause both impaired pancreatic beta-cell func-
tion and insulin resistance have been reported 
with low blood 25-hydroxyvitamin D levels.5 Ob-
servational studies support an association be-
tween a low blood 25-hydroxyvitamin D level and 
the risk of diabetes.6 In short-term mechanistic 
studies, vitamin D supplementation improved 
the disposition index, a measure of pancreatic 
beta-cell function, by 40%.7 However, whether 
vitamin D supplementation lowers the risk of 
diabetes is unclear.8-10 The Vitamin D and Type 2 
Diabetes (D2d) trial was conducted to test 
whether vitamin D supplementation reduces the 
risk of type 2 diabetes among adults at high risk 
for the disorder.
Me thods
Trial Design
This randomized, double-blind, placebo-controlled 
clinical trial evaluated the safety and efficacy of 
oral administration of vitamin D3 (cholecalciferol; 
4000 IU per day) for diabetes prevention in 
adults at high risk for type 2 diabetes.11 The 
trial protocol (available with the full text of this 
article at NEJM.org) was designed by the plan-
ning committee and the primary sponsor (Na-
tional Institute of Diabetes and Digestive and 
Kidney Diseases) without input from manufac-
turers11 and involved collaboration among 22 
academic medical centers in the United States 
(https://d2dstudy.org/sites). A sponsor-appointed 
data and safety monitoring board approved the 
protocol and provided independent monitoring 
of the trial. The institutional review board at 
each clinical site also approved the protocol, and 
all the participants provided written informed 
consent. The data were collected by trial-site 
personnel and stored in an electronic data-cap-
ture database. The statistical team at the coordi-
nating center analyzed the data and vouches for 
its accuracy. All the authors vouch for the accu-
racy and completeness of the data and for the 
fidelity of the trial to the protocol. They also 
contributed to the interpretation of the results 
and the preparation, review, and approval of the 
manuscript and made the decision to submit the 
manuscript for publication.
No pharmaceutical manufacturers contributed 
to the planning, design, or conduct of the trial. 
Trial pills were purchased from an independent 
nutritional-supplement manufacturing company 
that has no association with any members of the 
D2d Research Group.
Participants
Participants met at least two of three glycemic 
criteria for prediabetes as defined by the 2010 
American Diabetes Association (ADA) guidelines: 
fasting plasma glucose level, 100 to 125 mg per 
deciliter (5.6 to 6.9 mmol per liter); plasma glu-
cose level 2 hours after a 75-g oral glucose load, 
140 to 199 mg per deciliter (7.8 to 11.0 mmol per 
liter); and glycated hemoglobin level, 5.7 to 6.4% 
(39 to 47 mmol per mole).12 Other inclusion cri-
teria were an age of 30 years or older (25 years 
or older for American Indians, Alaska Natives, 
or Native Hawaiians or other Pacific Islanders) 
and a body-mass index (BMI, the weight in kilo-
grams divided by the square of the height in 
meters) of 24 to 42 (22.5 to 42 for Asian Ameri-
cans). A low serum 25-hydroxyvitamin D level 
was not an inclusion criterion.
Key exclusion criteria were any glycemic crite-
rion in the diabetes range,12 factors (other than 
hyperglycemia and race) affecting the glycated 
hemoglobin level, use of diabetes or weight-loss 
medications, or use of supplements containing 
vitamin D at a dose of more than 1000 IU per 
day or calcium at a dose of more than 600 mg 
per day. For a complete list of eligibility criteria, 
see the Supplementary Appendix (available at 
NEJM.org). The recruitment process relied pri-
marily on electronic-health-record identification 
of potentially eligible adults who were then 
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screened in person and, if qualified, had a sec-
ond screening visit to determine final eligibility 
according to measured fasting plasma glucose, 
2-hour post-load plasma glucose, and glycated 
hemoglobin at the central laboratory of the trial.13
Intervention and Procedures
Participants were randomly assigned to take a 
single, once-daily soft-gel pill containing either 
4000 IU of vitamin D3 or matching placebo. 
Randomization was block-stratified according 
to trial site, BMI (<30 or ≥30), and race (white 
or nonwhite). Participants received a bottle of 
trial pills at the time of randomization and every 
6 months thereafter. Bottles with unused pills 
were returned at each visit to estimate adherence.
To maximize the ability of the trial to observe 
a treatment effect, participants were asked to 
refrain from using diabetes-specific or weight-
loss medications during the trial and to limit the 
use of outside-of-trial vitamin D to 1000 IU per 
day from all supplements, including multivita-
mins. Because of concern that high intake of 
calcium from supplements may be associated 
with adverse outcomes, participants were asked 
to limit calcium supplements to 600 mg per day. 
During the trial, participants were provided with 
information on diabetes prevention through infor-
mation sheets and twice-yearly group meetings.
Follow-up visits occurred at month 3, month 6, 
and twice per year thereafter. Midway between 
the in-person visits, an interim contact (tele-
phone or email) took place. All visits and con-
tacts were designed to promote retention, encour-
age adherence to the trial regimen, and assess 
for diabetes, occurrence of adverse events, and 
use of high-dose vitamin D supplements, diabe-
tes medications, and weight-loss medications.
Outcomes
The primary outcome in this time-to-event analy-
sis was new-onset diabetes, based on annual 
glycemic testing of fasting plasma glucose, gly-
cated hemoglobin, and 2-hour post-load plasma 
glucose and semiannual testing of fasting plas-
ma glucose and glycated hemoglobin. If two or 
three of the glycemic measures met the 2010 
ADA thresholds for diabetes,12 the participant 
was considered to have met the diabetes out-
come. When only the measure for fasting plasma 
glucose or glycated hemoglobin met the thresh-
old, confirmatory testing was performed for the 
positive measure within 8 weeks. If only the 
measure for 2-hour post-load plasma glucose 
met the threshold, then a 75-g oral glucose-toler-
ance test to reassess all three glycemic measures 
was repeated. If the repeat measure was positive 
or both fasting plasma glucose and glycated 
hemoglobin were positive (in the case of a repeat 
oral glucose-tolerance test), then the participant 
was considered to have met the diabetes out-
come. A diagnosis of diabetes that was made 
outside the trial was validated by in-trial labora-
tory testing or adjudicated by an independent 
clinical-outcomes committee.
During the trial, research staff, caregivers, 
and participants were unaware of glycemic test 
results until a participant met the diabetes out-
come. Safety was assessed by means of partici-
pant report and annual fasting measurements of 
serum calcium, serum creatinine, and morning 
spot urine calcium:creatinine ratio (a rough esti-
mate of urine calcium excretion).14
Laboratory Testing
Serum calcium and creatinine were analyzed lo-
cally at each site, and the estimated glomerular 
filtration rate was calculated.15 Other blood and 
urine specimens were processed locally and 
shipped to the central laboratory. Glycated 
 hemoglobin was measured with the use of an 
ion-exchange high-performance liquid chroma-
tography method certified by the National Glyco-
hemoglobin Standardization Program.16 Plasma 
glucose was measured with the use of a hexoki-
nase method. Stored serum samples from the 
baseline, month 12, and month 24 visits were 
used to measure 25-hydroxyvitamin D by liquid 
chromatography–tandem mass spectrometry vali-
dated by a quarterly proficiency-testing program 
administered by the Vitamin D External Quality 
Assessment Scheme.17,18
Statistical Analysis
The trial was designed as an event-driven trial 
with a target of 508 diabetes events and a total 
sample size of 2382 participants assigned equal-
ly to the vitamin D group and placebo group, on 
the basis of a hypothesized hazard ratio of 0.75 
in the vitamin D group, an incidence of diabetes 
of 10% per year in the placebo group, a type I 
error rate of 0.0501 (with a single interim analy-
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sis taken into account), a power of 90%, a re-
cruitment period of 2 years, a trial duration of 
4 years, and a withdrawal rate of 5% per year 
of follow-up.19
Intention-to-treat analyses compared groups 
defined by the randomization procedure and in-
cluded all participants irrespective of adherence 
to the assigned intervention or to the protocol 
(e.g., use of diabetes or weight-loss medications). 
Follow-up time for all analyses was calculated as 
the time from randomization until the occur-
rence of the primary outcome, death, withdrawal, 
or last follow-up encounter free from diabetes. 
No imputation was performed for missing data, 
but we conducted a sensitivity analysis to assess 
for noninformative censoring of incomplete data 
(see the Supplementary Appendix).
Because the use of a diabetes-specific medi-
cation would be considered a “competing event” 
for the primary outcome, we prespecified a sen-
sitivity analysis in which the primary outcome 
was the time to new-onset diabetes according to 
trial criteria or use of a diabetes-specific medica-
tion. As planned in the protocol, we conducted an 
exploratory per-protocol analysis that censored 
follow-up data when a participant stopped the 
trial pills, started a diabetes or weight-loss medi-
cation, or took out-of-trial vitamin D from sup-
plements above the trial limit of 1000 IU per day.
The protocol specified that this event-driven 
trial would continue until the required number 
of diabetes events (508) was reached. A pre-
specified interim analysis for the data and safety 
monitoring board to examine harm or superior 
efficacy with the use of a Haybittle–Peto bound-
ary20 was conducted when approximately 70% of 
the required events (364 of 508) had accrued, 
and the data and safety monitoring board rec-
ommended that the trial proceed to its planned 
conclusion. Because the efficiency of event-driven 
trials is increased by stopping when the required 
number of events is achieved,21 we conducted 
blinded monitoring of event count and speci-
fied that when the trial was within approximately 
2 months of reaching 508 events, the subsequent 
scheduled follow-up visit for each participant 
would be considered the last visit. All events that 
occurred during the trial, including those that oc-
curred after the target of 508 events was reached, 
were used to generate the primary results.
Kaplan–Meier estimates were plotted for each 
group. Cox proportional-hazards models were 
used to calculate the hazard ratio for new-onset 
diabetes between the two groups.22 The model 
included group assignment as its main predictor 
variable and the stratification variables (trial site, 
BMI, and race). We also show a model without 
the stratification variables. Comparisons between 
the two groups at baseline and with respect to the 
rate of withdrawal, discontinuation of trial pills, 
use of diabetes or weight-loss medications, and 
supplemental intake above the trial limit used 
Fisher’s exact test, the chi-square test, the Wil-
coxon rank-sum test, or the pooled-variance 
t-test.
Variability of response to vitamin D supple-
mentation was assessed in prespecified subgroups 
defined by key baseline variables. Rates of ad-
verse events were compared between the two 
groups. When evaluating the significance of the 
prespecified subgroup analyses, we used the 
Hochberg sequential procedure to adjust for mul-
tiple comparisons, if necessary. No adjustments 
were made for the safety analyses or the planned 
exploratory or post hoc analyses for the primary 
outcome; therefore, only point estimates and 
95% confidence intervals are presented without 
P values.
R esult s
Participants
From October 2013 through February 2017, a to-
tal of 7133 persons were screened (Fig. 1), and 
2423 were randomly assigned to receive vitamin D 
(1211 participants) or placebo (1212 participants); 
these participants were included in the intention-
to-treat population (Table 1, and Table S1 in the 
Supplementary Appendix). A total of 44.8% of 
the participants were women, 33.3% were of non-
white race, and 9.3% were of Hispanic ethnic 
background.24 The participants had a mean age 
of 60.0 years, a mean BMI of 32.1, and a mean 
glycated hemoglobin level of 5.9% (48 mmol per 
mole). A total of 84.2% of the participants met 
the glycemic criteria for both fasting plasma 
glucose and glycated hemoglobin; approximately 
one third met all three glycemic criteria.
The last trial encounter was in November 2018. 
In the two groups, the median follow-up was 2.5 
years (interquartile range, 1.9 to 3.5 [vitamin D] 
and 1.7 to 3.5 [placebo]). Before reaching a pri-
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mary outcome event, 10 participants (5 in each 
group) died, and 62 (34 in the vitamin D group 
and 28 in the placebo group) withdrew consent 
(Fig. 1). In total, 99.1% of the cohort (1201 par-
ticipants in the vitamin D group and 1199 in 
the placebo group) contributed follow-up data, 
through either a visit that included central-labo-
ratory testing or a nonvisit encounter to capture 
a diagnosis of diabetes outside the trial.
The mean baseline level of serum 25-hydroxy-
vitamin D was 28.0 ng per milliliter (69.9 nmol 
per liter), with no significant difference between 
the two groups; 78.3% of the participants had a 
level equal to or greater than 20 ng per milliliter 
(50 nmol per liter) (Table 1). The mean 25-hydroxy-
vitamin D levels in the vitamin D group at 
month 12 (52.3 ng per milliliter [130.5 nmol 
per liter]) and month 24 (54.3 ng per milliliter 
[135.5 nmol per liter]) were higher than those 
in the placebo group (28.1 ng per milliliter 
[70.1 nmol per liter] and 28.8 ng per milliliter 
[71.9 nmol per liter], respectively) (Fig. S1 in the 
Supplementary Appendix).
Primary Outcome
By the end of the trial, diabetes had developed 
in 616 patients. New-onset diabetes (the primary 
outcome) occurred in 293 participants (273 cases 
diagnosed by trial-specific laboratory testing and 
20 diagnosed by adjudication) in the vitamin D 
group and 323 patients (305 cases diagnosed by 
trial-specific laboratory testing and 18 diagnosed 
by adjudication) in the placebo group (9.39 events 
and 10.66 events per 100 person-years, respec-
tively). The hazard ratio in the vitamin D group 
was 0.88 (95% confidence interval [CI], 0.75 to 
1.04; P = 0.12) (Fig. 2). When the stratification 
variables were not included in the model, the 
hazard ratio in the vitamin D group was 0.87 
(95% CI, 0.75 to 1.02). In a sensitivity analysis to 
account for missing data, the hazard ratio did 
not change substantially (see the Supplementary 
Appendix).
In the sensitivity analysis in which diabetes 
was defined as new-onset diabetes according to 
trial criteria or the use of a diabetes-specific 
medication, the hazard ratio in the vitamin D 
group was 0.88 (95% CI, 0.75 to 1.02). The re-
sults of the subgroup analyses were consistent 
with the findings of the main analysis; there 
was no apparent heterogeneity of treatment ef-
fect across the prespecified subgroups (Fig. 3). 
Figure 1. Screening, Randomization, and Follow-up.
One participant in the vitamin D group was withdrawn administratively after 
a clinical site closed down early in the trial. Protocol‑specified adverse events 
that led to discontinuation of the trial pills were hypercalcemia, a fasting 
urine calcium:creatinine ratio of more than 0.375, a low estimated glomerular 
filtration rate, and nephrolithiasis. Of the 2423 participants who underwent 
randomization, 14 (9 in the vitamin D group and 5 in the placebo group) 
were subsequently found not to meet all eligibility criteria.
2423 Underwent randomization
7133 Persons were assessed for eligibility
4710 Did not meet eligibility criteria
3850 Did not meet glycemic
criteria
106 Used supplements contain-
ing vitamin D at dose of
>1000 IU/day or calcium
at dose of >600 mg/day
159 Had abnormal laboratory
result
223 Withdrew consent or were
not interested
372 Had other reason
1211 Were assigned to receive
4000 IU of vitamin D daily
1211 Received vitamin D 
1212 Were assigned to receive
placebo daily
1211 Received placebo
1201 Completed ≥1 follow-up
encounter
1199 Completed ≥1 follow-up
encounter
1131 Met primary outcome, died, or
completed last follow-up encounter
1130 Met primary outcome, died, or
completed last follow-up encounter
1211 Were included in the intention-
to-treat analysis
1212 Were included in the intention-
to-treat analysis
3 Had no contact after randomi-
zation
5 Died
34 Withdrew
1 Was withdrawn administratively
137 Discontinued trial pills
27 Had protocol-specified adverse
event
20 Had other adverse event
86 Chose to discontinue
4 Had other reason
5 Had no contact after randomi-
zation
5 Died
28 Withdrew
108 Discontinued trial pills
24 Had protocol-specified adverse
event
13 Had other adverse event
66 Chose to discontinue
5 Had other reason
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In a post hoc analysis of data from participants 
with a baseline 25-hydroxyvitamin D level of less 
than 12 ng per milliliter (30 nmol per liter) (103 
participants), the hazard ratio in the vitamin D 
group was 0.38 (95% CI, 0.18 to 0.80). Among 
those with a baseline 25-hydroxyvitamin D level 
equal to or greater than 12 ng per milliliter 
(2319 participants), the hazard ratio in the vita-
min D group was 0.92 (95% CI, 0.78 to 1.08).
Adherence
A total of 170 participants (14.0%) in the vita-
min D group and 172 (14.2%) in the placebo 
group stopped trial pills, took diabetes or weight-
loss medications, or took outside-of-trial vita-
min D supplements above the trial limit before 
the diagnosis of diabetes. During the trial, more 
participants in the placebo group than in the 
vitamin D group started diabetes or weight-loss 
medications (Fig. S2 in the Supplementary Ap-
pendix). Although overall adherence to the trial 
regimen was high (85.8% of prescribed pills 
were taken), more participants in the vitamin D 
group (11.3%) than in the placebo group (8.9%) 
stopped trial pills (difference, 2.4 percentage 
points; 95% CI, 0.0 to 4.8) (Fig. S3 in the Sup-
plementary Appendix). During follow-up, more 
participants in the placebo group (5.2%) than in 
the vitamin D group (2.6%) reported use of 
outside-of-trial vitamin D supplements above the 
Characteristic
Overall 
(N = 2423)
Vitamin D 
(N = 1211)
Placebo 
(N = 1212)
Demographic
Age — yr 60.0±9.9 59.6±9.9 60.4±10.0
Female sex — no. (%) 1086 (44.8) 541 (44.7) 545 (45.0)
Race — no. (%)†
Asian 130 (5.4) 66 (5.5) 64 (5.3)
Black 616 (25.4) 301 (24.9) 315 (26.0)
White 1616 (66.7) 810 (66.9) 806 (66.5)
Other 61 (2.5) 34 (2.8) 27 (2.2)
Hispanic or Latino ethnic group — no. (%)† 225 (9.3) 120 (9.9) 105 (8.7)
Body‑mass index 32.1±4.5 32.0±4.5 32.1±4.4
Laboratory assessments
Fasting plasma glucose — mg/dl 107.9±7.4 108.0±7.4 107.8±7.4
2‑Hr post‑load plasma glucose — mg/dl 137.2±34.3 136.9±34.3 137.6±34.3
Glycated hemoglobin — % 5.9±0.2 5.9±0.2 5.9±0.2
Serum 25‑hydroxyvitamin D
Mean — ng/ml 28.0±10.2 27.7±10.2 28.2±10.1
Distribution — no./total no. (%)‡
<12 ng/ml 103/2422 (4.3) 60/1211 (5.0) 43/1211 (3.6)
12–19 ng/ml 422/2422 (17.4) 216/1211 (17.8) 206/1211 (17.0)
20–29 ng/ml 876/2422 (36.2) 453/1211 (37.4) 423/1211 (34.9)
≥30 ng/ml 1021/2422 (42.2) 482/1211 (39.8) 539/1211 (44.5)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. To convert the values for glu‑
cose to millimoles per liter, multiply by 0.05551. To convert the values for 25‑hydroxyvitamin D to nanomoles per liter, 
multiply by 2.496.
†  Race and ethnic group were reported by the participant. The category “other” includes American Indian or Alaska 
Native; Native Hawaiian or other Pacific Islander; and other race. Ethnic group includes any race.
‡  Categories of serum 25‑hydroxyvitamin D are based on the 2010 Dietary Reference Intakes for calcium and vitamin D 
recommended by the Food and Nutrition Board of the Institute of Medicine.23
Table 1. Baseline Characteristics of the Participants.*
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trial limit of 1000 IU per day (difference, 2.6 
percentage points; 95% CI, 1.1 to 4.2) (Fig. S2 in 
the Supplementary Appendix). There was no sig-
nificant difference between the two groups in the 
use of outside-of-trial calcium supplements above 
the trial limit.
In the exploratory per-protocol analysis that 
censored follow-up data when a participant start-
ed a diabetes or weight-loss medication, stopped 
the trial pills, or took out-of-trial vitamin D from 
supplements above the trial limit of 1000 IU per 
day, the primary outcome occurred in 265 par-
ticipants (21.9%) in the vitamin D group and 
304 (25.1%) in the placebo group (hazard ratio, 
0.84; 95% CI, 0.71 to 1.00).
Safety
There were no significant between-group dif-
ferences in the protocol-specified adverse 
events of interest: hypercalcemia, a fasting urine 
calcium:creatinine ratio of more than 0.375, a 
low estimated glomerular filtration rate, and 
nephrolithiasis (Table 2). Overall, 47 participants 
(3.9%) in the vitamin D group stopped the trial 
pills because of an adverse event, as compared 
with 37 (3.1%) in the placebo group (difference, 
0.8 percentage points; 95% CI, −0.7 to 2.3).
Discussion
In this multicenter, randomized, placebo-con-
trolled trial involving persons at high risk for 
type 2 diabetes not selected for vitamin D insuf-
ficiency, vitamin D3 supplementation at a dose of 
4000 IU per day did not result in a significantly 
lower risk of diabetes than placebo after a me-
dian follow-up of 2.5 years.
While our trial was being conducted, two 
other trials that were designed to test whether 
vitamin D supplementation lowers the risk of 
type 2 diabetes among persons at risk showed 
hazard ratios with vitamin D that were similar 
to those in our trial.25,26 In the Tromsø Vitamin D 
and T2DM Trial (Norway), which randomly as-
signed 511 white adults with prediabetes to 
20,000 IU per week (approximately 2900 IU per 
day) of vitamin D3 or placebo, the risk of diabe-
tes was numerically lower in the vitamin D group 
than in the placebo group, but the difference 
was not significant (hazard ratio, 0.90; 95% CI, 
0.69 to 1.18).25 In the Diabetes Prevention with 
Active Vitamin D study (Japan), which randomly 
assigned 1256 adults with prediabetes to an ac-
tive form of vitamin D analogue (eldecalcitol) 
or placebo, the risk of diabetes was also lower 
in the vitamin D group than in the placebo 
group, but the difference was again not signifi-
cant (hazard ratio, 0.87; 95% CI, 0.68 to 1.09).27 
We powered our trial to detect a 25% lower risk 
of diabetes with vitamin D than with placebo. 
On the basis of the results from all three trials, 
vitamin D supplementation may decrease diabe-
tes risk among persons at risk for diabetes not 
selected for vitamin D insufficiency by a smaller 
effect size (10 to 15%), but none of these trials 
were powered to test this effect size.
Our trial has several strengths. We used con-
temporary glycemic criteria to assemble a diverse 
cohort at high risk for diabetes with a hypergly-
cemic pattern closely matching how prediabetes 
is diagnosed in clinical practice, most commonly 
with fasting plasma glucose and glycated hemo-
globin. The vitamin D dose of 4000 IU per day 
Figure 2. Kaplan–Meier Curves for Survival Free from Diabetes among Adults 
at Risk for Type 2 Diabetes.
The hazard ratio for new‑onset diabetes between the vitamin D group and 
the placebo group is derived from Cox regression, with stratification accord‑
ing to trial site, body‑mass index, and race.
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was selected to balance safety and efficacy and 
resulted in a large difference in the serum 
25-hydroxyvitamin D level between the trial 
groups in the first 2 years of follow-up. In 94% 
of cases, the primary outcome was ascertained 
by trial-specific laboratory testing based on cur-
rent ADA criteria and required two tests in the 
diabetes range for diagnosis. Our cohort was 
recruited at a constant rate throughout the cal-
endar year, which reduced the potential of con-
founding by seasonal variability. Finally, the ob-
served rate of new-onset diabetes in the placebo 
group (10.7 events per 100 person-years) was 
consistent with our estimate of 10 events per 100 
person-years.
Overall adherence was high, and overall use 
of off-protocol concomitant therapies was low. 
However, among nonadherent participants, more 
Figure 3. Prespecified Subgroup Analyses.
Participants met at least two of three glycemic criteria for prediabetes: fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to 
6.9 mmol per liter); plasma glucose level 2 hours after a 75‑g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter) 
(impaired glucose tolerance); and glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mmol per mole). To convert the values for 25‑hydroxy‑
vitamin D to nanomoles per liter, multiply by 2.496.
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in the placebo group started diabetes or weight-
loss medications and took outside-of-trial vita-
min D supplements above the trial limit, whereas 
more in the vitamin D group stopped the trial 
pills for any reason. Whether these differences 
among nonadherent participants shifted the risk 
difference between the two groups toward or 
away from null in the intention-to-treat or per-
protocol analysis is unknown.
Response to a nutritional intervention de-
pends on nutritional status at baseline; thus, if 
vitamin D has an effect on diabetes prevention, 
persons with a higher baseline level of serum 
25-hydroxy vitamin D would be expected to 
have less effect from supplementation than those 
with a lower baseline level.28 Owing to ethical 
and practical considerations, a lack of consen-
sus on the preferred 25-hydroxyvitamin D level, 
and our desire to maximize the external valid-
ity of the trial, we specifically did not include 
serum 25-hydroxyvitamin D as an eligibility 
criterion. Because vitamin D supplements are 
used increasingly in the U.S. adult popula-
tion,29 approximately 8 of 10 participants had a 
baseline serum 25-hydroxy vitamin D level that 
was considered to be sufficient according to 
current recommendations (≥20 ng per milliliter) 
to reduce the risk of many outcomes,23,30 includ-
ing diabetes.6 The high percentage of partici-
pants with adequate levels of vitamin D may 
have limited the ability of the trial to detect a 
significant effect.
The vitamin D dose of 4000 IU per day is the 
recommended upper intake level to avert poten-
tial toxicity,23 although data from large trials on 
the safety on this dose have been scant. There is 
concern that 25-hydroxyvitamin D levels above 
50 ng per milliliter (125 nmol per liter) may be 
associated with adverse effects.23,30 In our trial, 
vitamin D3 supplementation at a dose of 4000 IU 
per day resulted in no significant differences be-
tween the two groups in the protocol-specified 
adverse events of interest (hypercalcemia, a fasting 
urine calcium:creatinine ratio of >0.375, a low 
estimated glomerular filtration rate, and nephro-
lithiasis). The 24-hour urine calcium level was not 
measured.31
In conclusion, among persons at high risk for 
type 2 diabetes not selected for vitamin D insuf-
ficiency, vitamin D3 supplementation at a dose of 
4000 IU per day did not result in a significantly 
lower risk of diabetes than placebo.T
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